- Home
- SELF vs BTAI Comparison
SELF vs BTAI Comparison
Compare SELF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | BTAI |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SELF | BTAI |
|---|---|---|
| Price | $5.01 | $2.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 41.4K | ★ 578.0K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | $752,000.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | $416.40 |
| P/E Ratio | $31.26 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $1.17 |
| 52 Week High | $5.89 | $9.26 |
Technical Indicators
Market Signals| Indicator | SELF | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 48.39 |
| Support Level | $4.97 | $1.82 |
| Resistance Level | $5.17 | $2.30 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 26.92 | 37.30 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.